CAPR as reported
Capricor Therapeutics, Inc. reported $22M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.
$22M
Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied
- Net Income
- −$115M
Net Income · +108% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$100M
Free Cash Flow · +114% year on year · trailing twelve months to Q1 2026
- EPS
- −$2.32
EPS · +69% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $22M | n/a | Q4 2024 · 5 quarters behind |
| Net Income | −$115M | +108% | Q1 2026 |
| EPS | −$2.32 | +69% | Q1 2026 |
| Op Margin | −286% | n/a | Q4 2024 · 5 quarters behind |
| Net Margin | −274% | n/a | Q4 2024 · 5 quarters behind |
| ROE | −60% | n/a | Q1 2026 |
| ROA | −45% | n/a | Q1 2026 |
| ROIC | 348% | n/a | Q4 2021 · 17 quarters behind |
| Free Cash Flow | −$100M | +114% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Capricor Therapeutics, Inc. (CAPR) - Revenue & ProfitRevenue & ProfitCapricor Therapeutics, Inc. (CAPR)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com